+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy

Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy

Medical Oncology 31(9): 185

The levels of serum beta-2 microglobulin (β2MG) are determined mainly from lymphoid tissue. To examine its prognostic value in Hodgkin lymphoma (HL), we conducted a retrospective analysis. We analyzed 67 patients with HL diagnosed and treated at seven institutes of the Yokohama City University Hematology Group between 1998 and 2011. The patients included 40 males and 27 females with a median age of 41 years (range 16-81 years). The HL subtypes were nodular sclerosis classical HL in 37 patients, mixed cellular classical HL in 23, lymphocyte-rich classical HL in 6, and nodular lymphocyte-predominant HL in 1. The 4-year overall survival (OS) rate of all 67 patients was 89 %. Patients with β2MG levels ≥ 2.5 mg/L (n = 18) showed inferior progression-free survival (PFS; 4-year PFS rate, 42 %) and inferior OS (4-year OS rate, 60 %) compared to patients who had β2MG levels <2.5 mg/L (n = 49; 4-year PFS rate, 87 %; 4-year OS rate, 98 %; P < 0.001). In multivariate analysis, only a serum β2MG level ≥ 2.5 mg/L was a significant adverse prognostic factor in regard to PFS (P = 0.04; relative risk 3.57). However, it was not significant prognostic factor for OS (P = 0.16) in the multivariate analysis. The serum β2MG level at diagnosis is a useful prognostic marker in patients with HL.

(PDF emailed within 0-6 h: $19.90)

Accession: 055212942

Download citation: RISBibTeXText

PMID: 25142947

DOI: 10.1007/s12032-014-0185-3

Related references

beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens. Journal of B.U.On. 10(1): 59-69, 2007

Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy. Leukemia and Lymphoma 56(11): 3096-3102, 2016

Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era. Oncotarget 7(44): 72219-72228, 2016

Prognostic significance of serum beta-2 microglobulin in patients with non-Hodgkin lymphoma. Oncology 87(1): 40-47, 2014

The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma. Haematologica 87(7): 701-8; Discussion 708, 2002

Serum beta-2 microglobulin as a prognostic factor in patients with Hodgkins lymphoma treated with A BVD or equivalent regimens with or without radiation therapy. Blood 102(11): 273b, November 16, 2003

Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2alphaR levels in non-Hodgkin's lymphoma. Leukemia and Lymphoma 33(5-6): 551-558, 1999

Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. British Journal of Haematology 175(2): 290-299, 2016

Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Annals of Oncology 20(11): 1848-1853, 2010

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. Oncotarget 7(47): 76934-76943, 2016

Clinical significance of serum lactate dehydrogenase, β2-microglobulin and vascular endothelial growth factor level detection in patients with non-Hodgkin's lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 20(3): 608-610, 2013

An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer 95(12): 2534-2538, 2002

The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients. Terapevticheskii Arkhiv 68(10): 28-31, 1996

Expression of COX-2 on Reed-Sternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD. Blood 119(25): 6072-6079, 2012